Carcell's Powertrain Platform
The Powertrain Platform is a unified platform core that accelerates the translation of therapeutic modalities from discovery to clinical proof-of-concept
Multiple platform technologies can be supported by the Powertrain Platform
Each technology platform has R&D independence and potential cross-platform synergies
Highly efficient use of capital and resources
IP Filing
and Portfolio Management
Chemistry, Manufacturing
and Controls
Fund Raising, Contracting and Partnership
Talent
Acquisition and
Organization Development
IND Filing
and Clinical Trials
Technology Platforms
Two lead technology platforms under development with support from the Powertrain Platform
%C2%A0.jpg)
Exogenously-Engineered Erythrocyte (E3)
The E3 platform generates engineered red blood cells (eRBCs) efficiently and cost-effectively. The products have great potential in treating autoimmune diseases and solid tumors. Carcell is developing the first therapeutic product candidate and quickly moving to CMC and scale-up production.
Carcell is developing its own proprietary lipid nanoparticles to deliver nucleic acids for a variety of applications. Lipid nanoparticles (LNPs) are clinically validated delivery vehicles that are less immunogenic than viral vectors and thus redosable. With different payload molecules, Carcell is leveraging its LNP platform to enable our collaborators to deliver their nucleic acid drugs
Carcell has a ligase, Readilase, that is capable of fast enzymatic ligation of proteins/peptides. Initially used in our E3 platform to produce eRBCs, we now seek to empower our collaborator's and client's ligation processes in view of developing a therapeutic drug or for research purposes.